Skip to content
Helping patients reclaim a life of possibility
Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE

Category: Myeloma

Myeloma EHA 2025 preview
Conferences, MyelomaJune 2, 2025
Join our EHA 2025 highlights webinar
Conferences, MyelomaJune 2, 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myeloma
Access, MyelomaApril 29, 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patients
Access, Myeloma, NewsMarch 3, 2025
treatment options
Watch the recording of the EHA 2023 highlights webinar
AL amyloidosis, MPE, Myeloma, VideosJuly 10, 2023
Watch the webinar “Importance of good nutrition and healthy diet for young myeloma patients”
Myeloma, VideosOctober 18, 2024
#FacesOfMyeloma: lessons from caring for a loved one with myeloma
MPE, MyelomaMarch 3, 2025
#FacesOfMyeloma: a story of hope and adaptation with Wouter
MPE, MyelomaMarch 3, 2025
#FacesOfMyeloma: Maureen’s path to living well with myeloma
MyelomaMarch 3, 2025
#FacesOfMyeloma: learning to live fully with myeloma
MPE, MyelomaMarch 3, 2025
12345…
67891011121314
15→
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month 2025
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.